Literature DB >> 15850568

Long-term cardiac gene expression using a coxsackieviral vector.

Byung-Kwan Lim1, Jae-Ok Shin, Sang-Chol Lee, Duk-Kyung Kim, Dong-Ju Choi, Seong-Choon Choe, Kirk U Knowlton, Eun-Seok Jeon.   

Abstract

Efficient myocardial gene transfer in the intact adult heart is difficult using conventional transfer vectors. Since coxsackievirus B3 (CVB3) is cardiotropic, it may be possible to exploit its cardiotropic characteristics to design a vector for gene transfer to the intact heart. We generated a recombinant CVB3 cDNA by inserting a green fluorescent protein (GFP) gene immediately upstream from the VP0 capsid protein of CVB3. The infectious virus (rCVB3-GFP) was recovered from the supernatants of the transfected Cos-7 cells, and was grown in HeLa cells to titers of 10(11) pfu/ml. In the rCVB3-GFP infected HeLa cells and neonatal rat cardiac myocytes, GFP protein expression was documented by immunoblot and by fluorescent microscopy. GFP expression was maintained after five passages in HeLa cells. To test in vivo expression of GFP, we infected 8-week-old inbred female Balb/C mice with 10(6) pfu of rCVB3-GFP, intraperitoneally. GFP was present in up to 30% of cardiac myocytes over the 8 weeks post infection (p.i.) and it was co-localized with CVB3 infection. Surprisingly, in spite of detection of GFP up to at least 8 weeks after infection, there was no mortality in the mice. It is possible to express exogenous proteins in the intact heart after an intraperitoneal (i.p.) injection of recombinant coxsackievirus. The duration of expression persisted for at least 8 weeks with little immune response nor mortality. These results demonstrated that the cardiac tropism of CVB3 could be used to design vectors for efficient gene expression in the intact heart.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15850568     DOI: 10.1016/j.yjmcc.2005.02.018

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  5 in total

Review 1.  Coxsackievirus B3-Its Potential as an Oncolytic Virus.

Authors:  Anja Geisler; Ahmet Hazini; Lisanne Heimann; Jens Kurreck; Henry Fechner
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

Review 2.  Therapeutic Use of Native and Recombinant Enteroviruses.

Authors:  Jani Ylä-Pelto; Lav Tripathi; Petri Susi
Journal:  Viruses       Date:  2016-02-23       Impact factor: 5.048

3.  Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines.

Authors:  Yanzhen Lin; Wei Wang; Junkai Wan; Ying Yang; Wenkun Fu; Dequan Pan; Linli Cai; Tong Cheng; Xiumin Huang; Yifeng Wang
Journal:  Virol J       Date:  2018-04-10       Impact factor: 4.099

4.  Vascular Endothelial Integrity Affects the Severity of Enterovirus-Mediated Cardiomyopathy.

Authors:  Jin-Ho Park; Ha-Hyeon Shin; Hyun-Seung Rhyu; So-Hee Kim; Eun-Seok Jeon; Byung-Kwan Lim
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

5.  CVB3-Mediated Mitophagy Plays an Important Role in Viral Replication via Abrogation of Interferon Pathways.

Authors:  Soo-Jin Oh; Byung-Kwan Lim; Jeanho Yun; Ok Sarah Shin
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.